Funding
← Back to your selection

EQT Life Sciences

Activity from announced rounds

Activity in this selectionSeries C+
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$74.4M
1 disclosed · full round size, not this investor’s share

By stage

Series C+2

By primary sector

Biotech1
Healthtech1

By country

Ireland1
Switzerland1

Rounds

2 in this selection
Nouscom

Clinical-stage biotech developing neoantigen-based cancer immunotherapies.

€120MSeries D
Participant
Neurent Medical

Neurent Medical develops NEUROMARK, a minimally invasive radiofrequency treatment for chronic rhinitis.

€62.5MSeries C
Role not disclosed